Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341505 | 0.89 | CCNA2 (0.43) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6826896 | 0.85 | CCNA2 (0.45) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6335444 | 0.82 | CCNA2 (0.39) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6335694 | 0.81 | ALDH1A1 (0.37) | CYP1A2MAPTERN1 | |
| SCHEMBL6403920 | 0.78 | CCNA2 (0.37) | CCNA2CDK2CCNA1 | |
| SCHEMBL6823841 | 0.78 | CDK2 (0.40) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6826015 | 0.78 | CCNA2 (0.40) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6335208 | 0.77 | MEN1 (0.40) | CCNA2CDK2CCNA1CYP1A2CYP2C19 | |
| SCHEMBL6828252 | 0.76 | CCNA2 (0.40) | CCNA2CDK2CCNA1CYP1A2MAPT | |
| SCHEMBL6336281 | 0.76 | CCNA2 (0.32) | CCNA2CDK2CCNA1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | CCNA2 2233/4885CDK2 2274/4885CCNA1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.